Osecon announced that the company's innovative drug liotinib tablets were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. Liotinib is a third-generation EGFR TKI with independent intellectual property rights, a novel molecular entity, and remarkable activity, jointly developed by the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences, Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences, and Jiangsu Osecon Pharmaceutical Co., Ltd. to treat EGFR mutant non-small cell lung cancer.

Osecon announced that the company's innovative drug liotinib tablets were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. Liotinib is a third-generation EGFR TKI with independent intellectual property rights, a novel molecular entity, and remarkable activity, jointly developed by the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences, Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences, and Jiangsu Osecon Pharmaceutical Co., Ltd. to treat EGFR mutant non-small cell lung cancer.